Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: Evidence for an effect on insulin extraction

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 5, 2001, Pages 2015-2019

  Kindmark, Henrik ^a   Pigon, Jan ^a   Efendic, Suad ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTROINTESTINAL HORMONE; GLIBENCLAMIDE; GLUCOSE DEPENDENT INSULINOTROPIC HORMONE; INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DRUG SYNERGISM; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE;

EID: 0035008535     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.5.2015     Document Type: Article

References (27)

1. La Barre J, 1927 Sur l'augumentation de la teneur en insuline du sang veineux pancreatique apres excitation du nerf vague. C R Seances Soc Biol Fil. 96:193-196.
2. Creutzfeldt W, Nauck M. 1992 Gut hormones and diabetes mellitus. Diabetes Metab Rev. 8:149-177.
3. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S. 1987 Effect of porcine gastric inhibitory polypeptide on β-cell function in type-1 and type-II diabetes mellitus. Metabolism. 36:677-682.
4. Nauck MA, Heimesaat MM, OØrskov C, Holst JJ, Ebert R, Creutzfeldt W. 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 91:301-307.
5. Fukase N, Igarashi M, Takahashi H, et al. 1993 Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabetic Med. 10:44-49.
6. Groop P-H. 1989 The influence of body weight, age and glucose tolerance on the relationship between GIP secretion and β-cell function in man. Scand J Clin Lab Invest. 49:367-379.
7. Beck B. 1989 Gastric inhibitory polypeptide: a gut hormone with anabolic functions. J Mol Endocrinol. 2:169-174.
8. Madsbad S, Kehlet H, Hilsted J, Tronier B. 1983 Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes. 32:436-438.
9. Groop P-H, Groop L, Tötterman KJ, Fyhrquist F. 1986 Relationship between changes in GIP concentrations and changes in insulin and C-peptide concentrations after guar gum therapy. Scand J Clin Lab Invest. 46:505-510.
10. Nauck MA, Homberger E, Siegel EG, et al. 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 63:492-498.
11. WHO Expert Committee on Diabetes Mellitus. 1985 Technical Report Series 727: Diabetes Mellitus. Geneva: WHO.
12. Faloona GR, Unger RH. 1974 Glucagon. In: Jaffe BM, Behrman HE, eds. Methods of hormone radioimmunoassay. New York: Academic Press; 317-330.
13. Meneilly GS, Bryer-Ash M, Elahi D. 1993 The effect of glyburide on β-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care. 16:110-114.
14. Shuster LT, Go VL, Rizza RA, O'Brien PC, Service FJ. 1988 Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes. 37:200-203.
15. Polonsky KS, Rubenstein AH. 1984 C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Diabetes. 33:486-494.
16. Schauder P, Brown JC, Frerichs H, Creutzfeldt W. 1975 Gastric inhibitory polypeptide: effect on glucose-induced insulin release from isolated rat pancreatic islets in vitro. Diabetologia. 11:483-484.
17. Szecowka J, Grill V, Sandberg E, Efendic S. 1982 Effect of GIF on the secretion of insulin and somatostatin and the accumulation of cyclic AMP in vitro in the rat. Acta Endocrinol (Copenh). 99:416-421.
18. Dupre J, Ross SA, Watson D, Brown JC. 1973 Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 37:826-828.
19. Ding W-G, Gromada J. 1997 Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic β-cells by glucose-dependent insulinotropic polypeptide. Diabetes. 46:615-621.
20. Kogire M, Inoue K, Sumi S, et al. 1992 Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs. Dig Dis Sci. 37:1666-1670.
21. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS. 1984 The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology. 115:1011-1018.
22. Hampton SM, Morgan LM, Tredger JA, Cramb R, Marks V. 1986 Insulin and C-peptide levels after oral and intravenous glucose. Diabetes. 35:612-616.
23. Limb C, Tamborlane WV, Sherwin RS, Pederson R, Caprio S. 1997 Acute incretin response to oral glucose is associated with stimulation of gastric inhibitory polypeptide, not glucagon-like peptide in young subjects. Pediatr Res. 41:364-367.
24. Dupré J, Behme MT, Hramiak IM, and Longo CJ. 1993 Hepatic extraction of insulin after stimulation of secretion with oral glucose or parenteral nutrients. Metabolism. 42:921-927.
25. Nauck MA, Busing M, Orskov C, et al. 1993 Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol. 30:39-45.
26. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. 1993 Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 133:2861-7280.
27. Jones IR, Owens DR, Vora J, Luzio SD, Hayes TM. 1989 A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the β-cell response or glucose tolerance in type-2 diabetes mellitus. Diabetes Res Clin Pract. 7:263-269.